Most Recent Articles by Douglas Strassler
Different clinical and neurobiologic pathways may be involved in treatment-resistant schizophrenia as it is not a homogeneous subgroup within the schizophrenia spectrum.
For patients with bipolar disorder and major depressive disorder, reduction in dose of antipsychotic medication could lead to an increased rate of hospitalization.
Augmentation therapy for treatment-resistant major depressive disorder includes multiple options with different strengths and limitations.
Children who are diagnosed on the autism spectrum are protected by their parents and community and are not properly actualized.
Updates made to the DSM-5 will clarify the diagnosis of bipolar disorder and related disorders.
More Articles by Douglas Strassler
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Lithium Monotherapy Effective in Treating Bipolar Disorder in Children
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Computerized Training Programs for Schizophrenia Improve Cognitive Functioning
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Cost-Effective Telehealth Alternatives for Veterans With Depression
- Polygenic Risk Scores Could Aid in Identifying Bipolar Disorder, Schizophrenia
- Brief Impression Questionnaire Useful in Schizophrenia Diagnoses